We’re pleased to announce that our team has officially moved into our new laboratories in BT4 at xista science park in Klosterneuburg.

Following several successful years in BT1, our new, expanded facilities provide additional laboratory and office space to support our continued growth and innovation. The move places us in the newly completed xista science park extension, which adds further state-of-the-art laboratories and office space for research- and technology-driven companies.

We look forward to continuing our work in this outstanding innovation ecosystem alongside our neighbours at xista science park and ISTA, and to welcoming partners and collaborators to our new space. 

For more information, contact: office@solgate.com

Solgate GmbH pursues the development of drugs modulating the activity of SLC proteins, focusing on the important roles of SLCs in neurological, autoimmune, and metabolic disorders. Through a proprietary discovery platform that combines several technologies, Solgate designs and rapidly advances novel chemical matter against selected SLCs. Solgate GmbH was founded by Ariel Bensimon, Georg Winter, Stefan Kubicek, Giulio Superti-Furga, and Gaia Novarino, together with CeMM and IST Austria.